Human Genome (HGSI) Reports a Q4 Loss; Announces Positive Interim Phase 2 Results for Albuferon, Initiates Phase 3 Trials
Tweet Send to a Friend
Human Genome (Nasdaq: HGSI) reports a Q4 GAAP loss of $0.50 (pro forma Q4 loss was $0.36) vs. consensus for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
